Patent · US Expired

Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1

US5541104A · kind A · utility

4Cited by

1References

4Claims

0Family size

Assignees

LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB
Cornell Research Foundation, Inc. · US

Inventors

Yao-Tseng Chen · New York, US
Elisabeth Stockert · New York, US
Yachi Chen · New York, US
Pilar Garin-Chesa · Biberach, DE
Wolfgang J. Rettig · Biberach, DE
Pierre van der Bruggen · Brussels, BE
Thierry Boon-Falleur · Brussels, BE
Lloyd J. Old · New York, US

Key dates

Filing date	Feb 1, 1994
Grant date	Jul 30, 1996
Priority date	—
Expiry date	Feb 1, 2014

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K39/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to monoclonal antibodies which specifically bind to the tumor rejection antigen precursor molecule MAGE-1, hybridomas which produce these monoclonal antibodies, and their use. Also described is a recombinant form of MAGE-1, peptides which are useful as immunogens, and immunogenic compositions containing the peptides and an adjuvant.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.